Company intelligence / Profile preview

Calando Pharmaceuticals

Pasadena, California, United Statescalandopharma.com ↗

Ownership: Private
Development stage: Other

Overview

Completed Phase 1 clinical trials for IT-101 in 2009 and initiated Phase 1 trial for CALAA-01 in 2008, which was the first clinical study using targeted, systemic delivery of siRNA in oncology. The company appears to be out of business as of the search results.

Therapeutic areas: Oncology
Modalities: siRNA therapeuticsNanoparticle drug formulations
Industry: Biotech

Drug pipeline

3 assets

RRM2 siRNA

2 more assets in the full pipeline.

Request access →

Partnerships

Cerulean Pharma Inc.

Beyond the preview

Go deeper on Calando Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calando Pharmaceuticals.

Explore the full profile